上海艾力斯医药科技股份有限公司成立于2004年3月，是一家以全球医药市场需求为导向，专注于肿瘤治疗领域，集新药研发、生产和商业化为一体的创新型制药企业。艾力斯医药以科技关爱生命为发展理念，以开发首创药物和同类最佳药物为首要目标。历经20年坚持不懈的努力，艾力斯已经成功自主研发，获批多款创新药，具备持续创制具有自主产权的、疗效确切的抗肿瘤新药之综合实力。2020年12月2日，上海艾力斯医药科技股份有 ...
KRAS is one of the most frequently activated oncogenes in human cancers. While the role of KRAS mutation in tumorigenesis and tumor maintenance has been extensively studied, the relationship between ...
引言这是一个关于细胞命运、时间顺序与生存博弈的故事。在肿瘤生物学的教科书里，我们习惯了线性的叙事：结直肠癌（Colorectal Cancer, CRC）的发展往往遵循着一个经典的剧本：从正常的肠道上皮出发，首先是肿瘤抑制基因 APC ...
14 天on MSN
Landscape of KRAS mutations and targeted therapies in colorectal cancer mapped in new study
A team of researchers from the Germans Trias i Pujol Research Institute (IGTP) and Institut Català d'Oncologia (ICO) has ...
Nivolumab (Nivo) plus ipilimumab (Ipi) 6-month treatment versus continuation in patients with advanced non-small-cell-lung cancer (aNSCLC): 3-year results of the IFCT-1701 DICIPLE phase 3 trial.
Garsorasib shrank tumours in nearly half of patients with KRAS G12C pancreatic cancer and showed manageable side effects.
The model suggests that negative KRAS findings are believable when the maximum of APC and TP53 frequencies is at least 8% (corresponding posterior probability of false negative <5%). Validation ...
Share on Pinterest New research shows certain KRAS mutations in pancreatic cancer may improve survival rates compared to other mutations. William Taufic/Getty Images In 2020, more than 495,000 adults ...
A common mutation in the KRAS gene is associated with improved overall survival in pancreatic ductal adenocarcinoma (PDAC) compared with other variants, in part because the mutation appears to lead to ...
Dr Sabari highlights typical outcomes for patients with NSCLC vs KRAS G12C-mutated NSCLC, as well as challenges associated with targeted treatments. One of the key problems with identifying and acting ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈